In a group of nondiabetic patients, postinfarction hyperglycemia was found to be closely associated with high levels of plasma immunoreactive glucagon (IRG).
IN RECENT years evidence has accumulated to suggest frequent abnormalities of carbohydrate intolerance in patients who suffer from acute or chronic heart disease.'1 A high incidence of hyperglycemia, or impaired glucose tolerance, in nondiabetic patients has been commonly observed, particularly following acute myocardial infarction.± Possible mechanisms for these metabolic changes have been considered, among them reduction in the available insulin6' 7or excessive secretion of "stress" hormones-catecholamines,8' 9 growth-hormone10 and cortisoll"-which are known to promote gluconeogenesis and glycogenolysis. However, while postinfarction hyperglycemia has been documented in noncomplicated infarctions4, 5 as well as in severe cases, most of the studies in which hormone determinations were done have showed that elevations of plasma cortisol, growth-hormone and catecholamines, while common in patients with severe infarction or in shock, were either rare or of a transient nature in the uncomplicated cases.11 '4 Diminished insulin secretion has also been found to be more common in patients with severe infarctions who exhibited low cardiac output or shock .15 Unger16 suggested recently that the concentration of extracellular glucose is normally maintained within its remarkably narrow limits by the combined but opposite effects of the two antagonist pancreatic hormones, insulin and glucagon. Insulin was considered as a hormone of energy storage, whereas glucagon may well be regarded as a hormone of energy release. In time of need, glucagon mobilizes energy-yielding metabolites from their tissue storage.
The purpose of this study was to determine whether excessive secretion of glucagon is a factor in the pathogenesis of post myocardial infarction hyperglycemia.
Patients and Methods Subjects
Fifteen patients who were admitted to the intensive coronary care unit in the Bronx Municipal Hospital Center with suspected acute myocardial infarction were the subjects of this investigation. The diagnosis of infarction was confirmed in eight of the patients (Group I) by positive and unequivocal diagnostic findings in serial electrocardiograms, and by significant but transient elevations in serum enzymes (CPK, SGOT, LDH). Group I was divided into Subgroups Ia where the mean of the glucose determinations was 135 mg% and Ib where the mean was 104 mg%. In the remaining seven patients (Group II), who suffered from various forms of chronic heart disease, a diagnosis of infarction was not established. This latter group was used as a control. Patients who were known to suffer from diabetes mellitus or who were treated during the study period with catecholamines or alpha or beta adrenergic blocking agents were excluded. Except for minor and transient arrhythmias (mostly during the first few hours following infarction), none of the Group I patients exhibited any major complication, and all survived and left the hospital. Pertinent clinical information is summarized in table 1. 4 and Datey and Nanda 5 were adopted for grading the curve as normal, abnormal, or diabetic.
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Procedures
Blood samples for laboratory determinations were obtained during a period of one week following admission. During that period all the patients were exposed to the same diet that was given routinely in the coronary care unit. Specimens were collected at least twice daily while the patients were in a fasting state, usually at 7:00 a.m. and 6:30 p.m. (lunch was given at 11:30 a.m.). Additional samples were collected two weeks later. All the patients were subjected to an oral glucose tolerance test performed during the latter half of the period of observation (some time between the fourth and seventh day after infarction). Samples were collected in the fasting state, and 60, 120 and 180 min following an oral intake of 75 g of glucose in the form of Glucola.* These samples were also analyzed for the three hormones. All samples were placed in ice immediately upon collection, and within 15-20 min were centrifuged in the cold. Plasma for hormone determinations was kept at -20°C for a later assay.
Analytical Methods
Serum glucose was determined in duplicate by the Neocuprin Technicon Autoanalyzer technique. Plasma immunoreactive insulin and growth-hormone were measured by radioimmunoassay according to the methods of Yalow and Berson17 and Glick et al. 18 Plasma immunoreactive glucagon (IRG) was measured in duplicate by a modification of the radioimmunoassay system described by Unger et al. 19 The antiglucagon antiserum was obtained from a guinea pig which was immunized with a commercial preparation of glucagon.* This antiserum showed cross-reaction with acidalcohol extracts of gastrointestinal tissues. However, the levels of IRG in the plasma of normal fasting subjects, measured when using this antiserum (ranging around 100 pg/ml), resembled very closely those described by Muller et al, 20 who used antiserum with a relatively high degree of specificity for pancreatic glucagon.
Moreover, when hyperglycemia was induced in normal subjects by glucose infusion, the levels of IRG as measured by this assay declined significantly. Repeated IRG measurements of the same sample on different assays showed reproducibility within 10%. The antiserum was diluted 1:250,000. Glucagon was labelled with 1251, and crystalline beef-pork glucagon was used as standard. Separation of free and bound glucagon-125I was carried out by using activated charcoal.
Statistics
Mean values with standard errors were calculated for grouped data and compared by the nonpaired t-test. Differences were considered significant if P was <0.05.
Results
Four patients in Group I showed consistently high concentrations of fasting blood glucose during the week of the study, and were therefore considered to exhibit postinfarction hyperglycemia (Subgroup Ia). The mean glucose concentration, *Ames Co., Inc., Elkart, Indiana. Group II patients (P < 0.001). There was no significant difference in any of the groups between the mean levels of the two daily IRG assays (morning and evening).
No correlation was found between growth hormone and glucagon concentrations, or between glucagon and insulin levels in the individual samples, in any of the groups. The mean concentrations of insulin and growth-hormone in each group are also presented in table 2. Plasma growthhormone concentrations were normal in all the patients and did not change following the glucose tolerance test.
-Determinations of the insulin/glucose ratio for the initial 60 min of the oral GTT (following the method described by Seltzer et al. )21 showed that the mean values of this index were abnormally low (insulin/glucose ratio < 1.0) in all three groups, with no differences between them, suggesting diminished insulin secretory response (and glucose tolerance) in all these groups. There were also no significant differences among the three groups in the response of plasma glucagon to the oral load of glucose (which was of no uniform pattern).
The individual measurements of fasting levels of both glucose and glucagon in Group Ia patients suggested a decline in concentration with evolution following infarction: smaller values were observed after the initial two or three days. To appreciate the Circulation, Volume XLVIII, October 1973 significance of the decline in glucose and glucagon levels with time, we divided arbitrarily the total duration of observation into an "early" (first three days) and a "late" (the following four days) period. The fall of glucose and glucagon concentrations in Group Ia patients during the seven day observation period is illustrated in figure 1 .
Discussion
This study provides the first information regarding a possible role of glucagon in the pathogenesis of hyperglycemia following myocardial infarction. Despite the small number of patients studied, it suggests that at least in certain cases, postinfarction hyperglycemia may be related to glucagon hypersecretion. In our study, only those patients whose plasma glucagon levels were significantly higher than the rest demonstrated high levels of fasting glucose. Moreover, the fall in glucose levels in the hyperglycemic group in the second period of observation was paralleled by a reduction in glucagon concentration. It is not clear whether the to the acute episode of infarction with elevations of plasma glucagon and glucose, suffered from the same metabolic disorder. As a result of other studies, some investigators have suggested alterations in alpha cell function and glucagon secretion in obesity,22' 23 and a defect in the suppression of glucagon secretion by hyperglycemia in diabetic patients. 19 Two of our four hyperglycemia patients were obese, and a third, while not overweight, suffered from an apparent disorder in lipid metabolism as evidenced by xanthelasma and high plasma levels of cholesterol and triglycerides. Three of the four patients in Subgroup la presented diabetic glucose tolerance tests. Diminished insulin secretory response was also a characteristic of Subgroup Ib and Group II. Recent observations demonstrated rises in the levels of glucagon in association with states of stress such as physical exertion24 and trauma. 25 It is conjectured that the major stress of myocardial infarction, acting through an unknown mechanism, induced hypersecretion of glucagon. An uninhibited increase in glucagon secretion in patients who might have suffered from a pre-existing metabolic disorder, could have resulted in the appearance of hyperglycemia.
Further investigations in similar and other groups of patients are indicated in order to clarify and evaluate more accurately the role of glucagon secretion in the pathogenesis of hyperglycemia in states of stress in general and in myocardial infarction in particular.
